M&A Deal Summary

CellaVision Acquires Ral Diagnostics SAS

On September 16, 2019, CellaVision acquired medical products company Ral Diagnostics SAS for 268M SEK

Acquisition Highlights
  • This is CellaVision’s 1st transaction in the Medical Products sector.
  • This is CellaVision’s 0th largest (disclosed) transaction.
  • This is CellaVision’s 1st transaction in France.

M&A Deal Summary

Date 2019-09-16
Target Ral Diagnostics SAS
Sector Medical Products
Buyer(s) CellaVision
Deal Type Add-on Acquisition
Deal Value 268M SEK

Target

Ral Diagnostics SAS

Martillac, France
Ral Diagnostics SAS is a producer and market actor in reagents in hematology, bacteriology, parasitology, cytology and pathology. The company’s reagents help to identify cell and tissue morphology, parasites and bacteria that are necessary to diagnose many illnesses. RAL supplies innovative products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing. Ral Diagnostics was formed in 1918 and is based in Martillac, France.

Search 198,242 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

CellaVision

Lund, Sweden

Category Company
Founded 1994
Sector Medical Products
Employees221
Revenue 677M USD (2023)
DESCRIPTION

CellaVision is a global medical technology company focused on developing and selling systems for routine analysis of blood and other body fluids in health care services. The analyses often constitute important reference data for fast and correct diagnosis of illnesses. CellaVision’s products rationalize manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. CellaVision was formed in 1994 and is based in Lund, Sweden.


DEAL STATS #
Overall 1 of 1
Sector (Medical Products) 1 of 1
Type (Add-on Acquisition) 1 of 1
Country (France) 1 of 1
Year (2019) 1 of 1